HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease

Br J Cancer. 2002 Oct 7;87(8):905-8. doi: 10.1038/sj.bjc.6600564.


The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser-->Leu 217) and (Ala-->Thr 541). The Thr541 variant in the HPC2/ELAC2 gene has previously been reported to be at an increased frequency in prostate cancer cases. To evaluate this hypothesis we genotyped 432 prostate cancer patients (including 262 patients diagnosed <or=55 years) and 469 UK, population based control individuals with no family history of cancer. We found no significant difference in the frequencies of Thr541-containing genotypes between cases and controls (OR=1.41, 95% CI 0.79-2.50). The association remained non-significant when the analysis was restricted to cases divided by age of onset into those diagnosed <or=55 years (OR=1.50, 95% CI 0.79-2.85) or to patients diagnosed >55 years (OR=1.27, 95% CI 0.59-2.74). We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • DNA / blood
  • DNA / genetics
  • DNA, Neoplasm / metabolism
  • Female
  • Genetic Predisposition to Disease / genetics*
  • Genetic Variation / genetics
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Mutation / genetics*
  • Neoplasm Proteins / genetics*
  • Odds Ratio
  • Polymorphism, Genetic*
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Risk Factors


  • DNA, Neoplasm
  • ELAC2 protein, human
  • Neoplasm Proteins
  • DNA